The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort
Abstract
HMG-coA reductase inhibitors, commonly known as statins, account for the great majority of cholesterol-lowering drug use. However, little is known about the association between long-term statin use and incidence of most types of cancers. We examined the association between long-term use of cholesterol-lowering drugs, predominantly statins, and the incidence of ten common cancers, as well as overall cancer incidence, among 133,255 participants (60,059 men and 73,196 women) in the Cancer Prevention Study II Nutrition Cohort during the period from 1997 to 2007. Multivariate Cox proportional hazards regression was used to estimate relative risks (RR). Current use status and duration of use were updated during follow-up using information from biennial follow-up questionnaires. Current use of cholesterol-lowering drugs for five or more years was not associated with overall cancer incidence (RR = 0.97, 95% CI = 0.92–1.03), or incidence of prostate, breast, colorectal, lung, bladder, renal cell, or pancreatic cancer but was associated with lower risk of melanoma (RR = 0.79, 95% CI = 0.66–0.96), endometrial cancer (RR = 0.65, 95% CI = 0.45–0.94), and non-Hodgkin lymphoma (NHL; RR = 0.74, 95% CI = 0.62–0.89). These results suggest that long-term use of statins is unlikely to substantially increase or decrease overall cancer risk. However, associations between long-term statin use and risk of endometrial cancer, melanoma, and NHL deserve further investigation. Cancer Res; 71(5); 1763–71. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Morton, L. M., Turner, J. J., Cerhan, J. R., Linet, M. S., Treseler, P. A., Clarke, C. A., Jack, A., Cozen, W., Maynadié, M., Spinelli, J. J., et al. (2007) · Blood · doi:10.1182/blood-2006-11-051672 · Cited by 387 · cited 2×
“Shorter-term use of cholesterol-lowering drugs also was associated with lower risk of NHL. Results for NHL shown in Table 2 are based on a broad definition of NHL recently recommended for epidemiologic research by the International Lymphoma Epidemiology Consortium (17).”
Method
Cited by
The Epidemiology of Pancreatitis and Pancreatic Cancer
Yadav, D., & Lowenfels, A. B. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.068 · Cited by 1,974
Bade, B. C., & Dela Cruz, C. S. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.10.001 · Cited by 1,911
The Role of Cholesterol in Cancer
Kuzu, O. F., Noory, M. A., & Robertson, G. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2613 · Cited by 708
Triple-negative breast cancer: is there a treatment on the horizon?
Yao, H., He, G., Yan, S., Chen, C., Song, L., Rosol, T. J., & Deng, X. (2017) · Oncotarget · doi:10.18632/oncotarget.12284 · Cited by 394
Cholesterol and prostate cancer
Pelton, K., Freeman, M. R., & Solomon, K. R. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.07.006 · Cited by 303
Metadata
- Authors
- Jacobs, E. J., Newton, C. C., Thun, M. J., & Gapstur, S. M.
- Venue
- Cancer Research
- Published
- 2011-03-01
- Volume
- 71
- Issue
- 5
- Pages
- 1763-1771
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1971403921
- Cited by
- 222
- References
- 1
- FWCI
- 7.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort. https://app.cochat.ai/papers/10.1158/0008-5472.can-10-2953
- The paper
- Jacobs, E. J., Newton, C. C., Thun, M. J., & Gapstur, S. M. (2011). Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort. Cancer Research. https://doi.org/10.1158/0008-5472.can-10-2953
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.